Suppr超能文献

阿霉素与维拉帕米联合膀胱灌注预防浅表性膀胱肿瘤复发

[Intravesical instillation of combined adriamycin and verapamil in preventing recurrence of superficial bladder tumor].

作者信息

Liu N B

机构信息

China-Japan Friendship Hospital, Beijing.

出版信息

Zhonghua Wai Ke Za Zhi. 1993 Jun;31(6):330-2.

PMID:7906217
Abstract

Multidrug-resistance of the tumor cells is the main cause for failure of chemotherapy. Such resistance is correlated to P-glycoprotein 170, which can pump the chemotherapeutic agent out of the tumor cells. This action could be reversed by verapamil through competition for closely related binding sites on P-glycoprotein. Twenty-four postoperative cases of superficial bladder tumors were treated by intravesical instillation of combined adriamycin and verapamil, and they were followed up for 17-35 months (average 24.5 months). Two cases (8.7%) had recurrence. NO marked toxicity and side-effects were observed. Verapamil working as a drug-resistance reversing agent might be used in some other tumors not sensitive to chemotherapy.

摘要

肿瘤细胞的多药耐药性是化疗失败的主要原因。这种耐药性与P-糖蛋白170相关,P-糖蛋白170可将化疗药物泵出肿瘤细胞。维拉帕米可通过竞争P-糖蛋白上密切相关的结合位点来逆转这一作用。24例浅表性膀胱肿瘤术后患者采用阿霉素与维拉帕米联合膀胱灌注治疗,随访17 - 35个月(平均24.5个月)。2例(8.7%)复发。未观察到明显的毒性和副作用。维拉帕米作为一种耐药逆转剂可能用于其他对化疗不敏感的肿瘤。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验